Capricor Therapeutics Completes Enrollment of Phase II Clinical Trial for Cenderitide to Treat Heart Failure

By: via Benzinga
Capricor Therapeutics, Inc. (Nasdaq: CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.